Atosiban is usually continued for 45-48 hours, with continued use not recommended after 48 hours. Atosiban is an antagonist of oxytocin, which is a synthetic peptide, applied to preterm labor, it can inhibit uterine contractions, make the uterus quiet, and be used to delay the occurrence of preterm labor in patients with a tendency to preterm labor, and the clinical use of atosiban is generally continued for 45-48 hours, and it is not recommended to continue to use it after 48 hours. Atosiban is a prescription drug, which must be prescribed by a doctor and used in strict compliance with the doctor’s instructions. It must be used by a doctor who has experience in treating preterm labor and must not be used arbitrarily on its own; uterine contractions and fetal heart rate should be monitored during the period of Atosiban treatment; Atosiban can only be used in pregnant women over 18 years old, with a gestational age of 24-33 weeks and a normal fetal heartbeat examination. Atosiban should not be used if: gestational age is less than 24 weeks or more than 33 weeks; premature rupture of membranes greater than 30 gestational weeks; intrauterine fetal growth retardation and fetal heartbeat abnormality; antepartum uterine bleeding requiring immediate delivery; fetal demise in the uterus; suspicion of intrauterine infection; any condition in which continuation of the pregnancy is detrimental to the mother and the fetus; and a known hypersensitivity to atosiban or any of its excipients. Treatment with atosiban should not exceed 48 hours, and once the diagnosis of preterm labor has been made, treatment with the first single-dose intravenous push should be initiated as soon as possible, with intravenous drip therapy following completion of the single-dose push.